Bio-Techne To Be Acquired by Merck KGaA

Moderna (MRNA) and Merck (MRK) announced positive Phase 3 trial results for their personalized mRNA cancer vaccine combined with Keytruda, meeting primary goals. Moderna's shares surged 177%, adding $44 billion to its market value, while Merck's shares rose 12%. The trial showed extended time without melanoma recurrence and reduced risk of cancer spread. Moderna CEO called it a validation of a new class of medicine, with analysts expecting regulatory approval soon.

Moderna (MRNA) and Merck (MRK) announced their personalized melanoma vaccine, intismeran, combined with Keytruda, met Phase 3 trial goals, reducing cancer recurrence risk. Both companies' shares rose on the news. Full data will be presented at an upcoming medical meeting. Additional trials are ongoing for other cancers.

Merck (MRK) rose 12% on August 19 after its melanoma vaccine met Phase 3 goals, reaching an all-time high of $154.49 before dropping to $149.54. Analysts' price targets range from $150 to $179. The stock trades near fair value with a 2.3% dividend yield. Key support is at $149.49, and resistance at $154.65. Full data on the vaccine is expected in October.

Moderna and Merck reported success in a late-stage trial of their mRNA cancer vaccine for melanoma, marking a breakthrough after over a century of failed attempts. The vaccine, personalized for each patient, showed efficacy in preventing tumor recurrence. Wall Street estimates potential sales in the billions. Merck faces Keytruda patent expiration, while Moderna seeks new growth avenues. Both companies plan further trials and data analysis. Moderna's shares surged over 130% post-announcement.

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

Moderna is raising $2 billion in convertible debt following the success of its personalized cancer vaccine developed with Merck. The vaccine uses an algorithm to analyze tumor mutations and create a bespoke mRNA treatment. Some investors question the necessity of personalization. Meanwhile, a U.S. biotech crackdown on China could benefit European companies, and a rival drug failure may impact Alnylam's ATTR-CM franchise.